The 2026 WHO dementia guideline keeps blood-pressure control as a core way to lower dementia risk. For adults over 65, it means continuing prescribed hypertension treatment plus activity, healthy diet, and social, cognitive, hearing and vision care. Hypertension means blood pressure that stays too high over time. WHO released the update on 15 July 2026 as a second edition of its 2019 dementia risk-reduction guideline, concluding up to 45% of dementia risk could be prevented or delayed by acting on modifiable factors, according to WHO in the WHO announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Read the official guidance from Who — Use this primary source to verify the official guidance.
- Read the official guidance from Nature — Use this primary source to verify the official guidance.
Table of Contents
- Is there a new blood-pressure rule?
- Why does timing matter?
- What target should you discuss with your doctor?
- What are the limits?
Is there a new blood-pressure rule?
There is no new dementia drug or separate dementia blood-pressure test for older adults. The practical message is continuity: keep treating hypertension and add daily habits that support brain and heart health.
The guideline speaks mainly to policymakers and health workers. UN News reports that it asks them to build dementia prevention into routine primary care across the life course, including blood-pressure, diabetes and cholesterol control, in the UN report. For readers, that points to the regular clinic visit as the main place for prevention.
Why does timing matter?
Midlife blood pressure predicts late-life dementia better than late-life pressure alone. The WHO professional summary therefore stresses screening and managing cardiovascular risks in midlife, including hypertension, obesity and dyslipidaemia.
That history still matters after 65. WHO and PAHO list hypertension with diabetes, high cholesterol, tobacco use, alcohol use, inactivity, isolation and air pollution as modifiable risks, and say managing hypertension can help reduce dementia risk. Medical News Today describes the over-65 implication as continued hypertension treatment plus activity, diet, social and cognitive engagement, and hearing and vision care.
What target should you discuss with your doctor?
The WHO guideline itself does not set a personal drug dose. The 2025 AHA/ACC multisociety adult hypertension guideline recommends a systolic goal below 130 mmHg in adults with hypertension to help prevent mild cognitive impairment and dementia, as summarized by Hypertension Research/Nature in the hypertension research summary.
The strongest recent trial support comes from the 4-year CRHCP-3 study of 33,995 adults age 40 and older with uncontrolled hypertension. JACC Advances reports that intensive control below 130/80 lowered new all-cause dementia by 15% compared with usual care, in the JACC Advances study. Use that evidence as a discussion prompt, not a self-prescription:.
- Ask what systolic and diastolic range fits your age, kidney function, and fall risk
- Ask how often to check pressure at home and what reading should trigger a call
- Review all blood-pressure, diabetes, cholesterol, sleep, mood, hearing and vision medicines at each visit
What are the limits?
Blood-pressure control lowers probability; it does not guarantee prevention. A SageWiz review notes the WHO hypertension management recommendation is conditional with low or very low certainty evidence, and age remains the strongest dementia risk factor.
That makes steady follow-through more useful than seeking a perfect number. Keep taking prescribed treatment, stay active, eat a balanced diet, stay socially and mentally engaged, and get hearing and vision checked. Bring your home readings and medication list to your next primary-care visit.
You Might Also Like
- Maine’s 2026 ECHO Training for Dementia Risk Reduction: What Is Established and What Remains Uncertain for Family Caregivers
- FDA’s 2026 At-Home Leqembi IQLIK Starting Dose: What the News Means for People With Mild Cognitive Impairment
- At-Home Leqembi vs IV Infusions After the 2026 FDA Decision: What the News Means for People With Mild Cognitive Impairment
